DETAILED ACTION
Final
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Response to Amendment
The amendment filed on 06/26/2026 is entered and acknowledged by the Examiner. Claims 1, 7-8, and 13-17 have been amended. Claims 4-5 and 9-10 have been canceled. Claims 1-8 are currently pending in the instant application.
The rejection of claims 1-5 and 7-17 under 35 U.S.C. 102(a)(1) as being anticipated by Sang (KR 20130114436 A) is withdrawn in view of Applicant’s amendment and remark.
The rejection of claim 6 under 35 U.S.C. 103 as being unpatentable over Sang (KR 20130114436 A) in view of ‘372 (KR 201330042372 A) and Cok (US 2008/0237611 A1) is withdrawn in view of Applicant’s amendment and remark.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claims 2 and 11 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Independent claims 1 and 7 recite an alkanolamine includes ethanolamine or butanolamine, respectively. Ethanolamine and butanolamine are known to have an alkane skeleton of 2 and 4 carbon atoms, respectively. Claims 2 and 11 depend from claims 1 and 7 require the alkanolamine to contain alkane skeleton of 1 to 5 carbon atoms. Claims 2 and 11 failed to further limit the carbon atoms of the alkanolamine in claims 1 and 7.
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Allowable Subject Matter
Claims 1, 3, 6-8, and 12-17 are allowable over the prior art of record.
The following is an examiner’s statement of reasons for allowance: the claims, filed on 06/26/2026, have been carefully reviewed and searched.
Currently, there is no prior art alone or in combination that teaches or fairly suggests a quantum-dot -containing film having a molar ratio of alkanolamine to inorganic ligands in a range of 10 to 1,000 and a molar ratio of ethanolamine or butanolamine to S2- in a range of 10 to 1,000 as recited in amended claims 1 and 7. Therefore, claims 1 and 7 are allowable over the prior art of record. Claims 3, 6, 8, and 12-17 directly or indirectly depend from claims 1 and 7 and are allowable based on their dependencies.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KHANH TUAN NGUYEN whose telephone number is (571)272-8082. The examiner can normally be reached M-F 9:00 AM to 5:00 PM EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Angela Brown-Pettigrew can be reached at (571) 272-2817. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KHANH T NGUYEN/Primary Examiner, Art Unit 1761
Prosecution Insights